Pharma News

Zydus Lifesciences Limited announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2025, showcasing strong growth across all major business segments.

Pfizer Inc. issued a firm response following a ruling by the Court of Chancery of the State of Delaware that denied Pfizers request for a temporary restraining order to block Metsera, Inc. from terminating its merger agreement and accepting a competing proposal from Novo Nordisk A/S.

AstraZeneca has reported a strong set of results for the first nine months and third quarter of 2025, highlighting double-digit revenue growth, rising earnings, and record progress in its late-stage pipeline.

Through a new research and development funding agreement, the company will receive $700 million from Blackstone Life Sciences to support late-stage clinical development of sac-TMT.

In a compelling report released today, Novo Nordisk A/S (Bagsværd, Denmark) announced robust performance for the first nine months of 2025 along with noteworthy pipeline developments that reflect the company’s ambition to redefine the treatment of chronic and rare diseases.

In a historic leap for global health, an international team of scientists has developed the world’s first genetically engineered, product-ready snake antivenom — a potential game-changer for treating bites from some of Africa’s most lethal snakes, including cobras, mambas, and rinkhals.

The U.S. Food and Drug Administration (FDA) has announced new measures aimed at accelerating the development of biosimilar medicines and lowering the overall cost of biologic treatments in the United States.

Pharmaceutical major Cipla Limited has announced the signing of definitive agreements to acquire 100% equity stake in Inzpera Healthsciences Limited, a company engaged in developing and marketing differentiated paediatric and wellness products. The announcement was made through a corporate filing with the Bombay Stock Exchange

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received tentative approval from the United States Food and Drug Administration (USFDA) for Budesonide delayed-release capsules, 4 mg (USRLD: Tarpeyo Capsules, 4 mg).